Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How Far Can Big Pharma Collaboration Go? Much Further, Executives Say

This article was originally published in The Pink Sheet Daily

Executive Summary

Big pharma collaborations and other new or once-rare models of business development can help companies ‘do more with less’, according to AstraZeneca’s and Merck’s heads of business development, who spoke at Elsevier’s Pharmaceutical Strategic Alliances conference.

You may also be interested in...



2012’s Top Biopharma Dealmakers

AstraZeneca was the top in-licenser, snagging a $3.4 billion pact with BMS for Amylin’s diabetes assets, making metabolic diseases the leading therapeutic area in biopharma alliances.

“The Pink Sheet” DAILY – Most Notable Stories Of 2012

A baker’s dozen stories from the past year that captured reader interest and reflected biopharma trends.

Bristol And AstraZeneca Make A Splash In Diabetes With Joint Purchase Of Amylin

Bristol-Myers’ and AstraZeneca’s deal to acquire Amylin Pharmaceuticals for $7 billion, announced June 29, reaffirms the partners’ commitment to the vast and growing type 2 diabetes market, even if the competition is intense and the companies’ five-year-old alliance got off to a rocky start.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS074709

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel